Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

2016 Recombinant Protein and Antibody Drug R&D Seminar

Page View:

China Pharmaceutical University and Hefei Chaohu, Economic Development Zone, successfully co-hosted the “2016 Recombinant Protein and Antibody Drug R&D Seminar” at Shenye Holiday Inn Hot Spring Resort recently. Medicilon congratulated the successful seminar hosting and sincerely thanked all the colleagues and peers from the pharmaceutical industry who attended this seminar for their sharing. As one of the co-organizers, Medicilon received a lot of attention!

Medicilon's antibody development technical service discount covers the full line of ADA antibody development technical services and druggable antibody development technical services. The 20% off discount applies to the completion of ADA rabbit polyclonal antibody development, ADA mouse hybridoma monoclonal antibody development, phage display rabbit monoclonal antibody development services, mouse monoclonal antibody development technical services, mouse/rabbit single B cell antibody development technical services, etc.

During the seminar, the organizers invited several well-known experts and scholars to conduct in-depth discussions and communication with participants on various topics, such as MAb and ADC pharmacokinetics and the latest research progress and the prospect of Biologics, through presentations and panel discussions. It played a significant role in promoting the Development of the pharmaceutical industry.


Photos From the Seminar and Panel Discussion

Guozhen Xu, VP of Sinobioway Bioeconomy Group Co., LTD. hosted the opening ceremony


Dr. Min Wang, President of China Pharmaceutical University, delivered the welcoming speech


Dr. Ji Li, Vice Chairman of Pharmaceutical Society of Jiangsu Province, delivered a welcoming speech


Dr. Yuexi Li, Vice Chairman of Biochemistry and Molecular Biology Society of Jiangsu Province, delivered a welcoming speech


Wenbo Cao, CEO of Sinobioway Bioeconomy Group, delivered a welcoming speech


Professor Min Wang from China Pharmaceutical University hosted the academic symposium


Huiping Chen from CFDA Audit Center reported for the analysis of common problems in biological products inspection


Dr. Xingchu Gu, VP of Medicilon’s Preclinical Research, reported on preclinical safety evaluation of therapeutic monoclonal antibody


Zongmin Wang, Director of Jiangsu Province Food and Drug Administration Registry, explained on the Reform Policy of Drug Examination and Approval


Dr. Chunlin Chen, CEO of Medicilon, hosted the panel discussion


Professor Yu Liu (Left) and Professor Hanmei Xu (Right) from China Pharmaceutical University hosted the panel discussion


Professor Zichun Hua from Nanjing University reported on long-term effects of protein drugs


Professor Chunmin Rao from National Institute of Food and Drug Control reported on recombinant and antibody drug quality control research


Professor Min Wang from China Pharmaceutical University reported on development of monoclonal antibody in China


Dr. Xiangyang Zhu, General Manager of Huabo Biopharm, reported on the progress antibody drugs research


Dr. Wenzhi Tian from ImmuneOnco shared the experience on antibody drug R & D


Dr. Juan Zhang, Vice Professor of China Pharmaceutical University, reported on the research of anti-tumor angiogenesis antibody JZB01

Related Articles:

Medicilon Assists | China's First CD19×CD3×CD28 Trispecific Antibody Obtained FDA Implicit Approval

Medicilon Assistant| Jimincare's lgE Antibody Drug JYB1904 has been Approved for Clinical Trials

Medicilon assisted Bio-Thera's bispecific neutralizing antibody drug for injection BAT2022 for the treatment of new coronary pneumonia was approved for clinical use

Relevant newsRelevant news